News & Updates

Add-on metoprolol of no benefit to high-risk prostate cancer patients
Add-on metoprolol of no benefit to high-risk prostate cancer patients
29 Sep 2021

Use of metoprolol among high-risk prostate cancer patients receiving androgen deprivation therapy does not appear to improve oncological outcomes, as shown in a study.

Add-on metoprolol of no benefit to high-risk prostate cancer patients
29 Sep 2021
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
28 Sep 2021 byJairia Dela Cruz

In the treatment of patients with type 2 diabetes mellitus and hypertension, switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor to the sodium-glucose cotransporter-2 (SGLT2) inhibitor luseogliflozin appears to have favourable effects on blood pressure (BP), circadian rhythm, and night-time systolic BP (SBP) and pulse rate (PR), according to data from the open-label LUNA trial.

DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
28 Sep 2021